EternoGen, a startup developing a botox alternative, raises $1m in series A round from unspecified backers.

University of Missouri-Columbia startup EternoGen, which is commercialising a potential rival to aesthetic beauty treatment botox, has received $1.065m from unspecified backers.

In addition, the Columbia-based firm said that it anticipates a further $500k following significant interest from investors.

EnternoGen is developing collagen replenishment therapies which could potentially rival the well-established beauty treatment botox, used by aesthetic physicians to treat aging skin, and compete in a worldwide market estimated to be worth an annual $2bn with an expected growth rate…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?